- PA5-27349 - Invitrogen Antibodies GLA antibody

Submitted references Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.

Monticelli M, Liguori L, Allocca M, Bosso A, Andreotti G, Lukas J, Monti MC, Morretta E, Cubellis MV, Hay Mele B
International journal of molecular sciences 2022 May 4;23(9)

Characterization of Mono- and Bi-Transgenic Pig-Derived Epidermal Keratinocytes Expressing Human FUT2 and GLA Genes-In Vitro Studies.

Wiater J, Samiec M, Wartalski K, Smorąg Z, Jura J, Słomski R, Skrzyszowska M, Romek M
International journal of molecular sciences 2021 Sep 7;22(18)

Trichostatin A-Assisted Epigenomic Modulation Affects the Expression Profiles of Not Only Recombinant Human α1,2-Fucosyltransferase and α-Galactosidase A Enzymes But Also Galα1→3Gal Epitopes in Porcine Bi-Transgenic Adult Cutaneous Fibroblast Cells.

Wiater J, Samiec M, Skrzyszowska M, Lipiński D
International journal of molecular sciences 2021 Jan 30;22(3)

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Galactosidase alpha in Rat tissue extracts (50 µg). Samples was separated by 10% SDS-PAGE and the membrane was probed with Galactosidase alpha Polyclonal antibody (Product # PA5-27349) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using alpha Galactosidase Polyclonal Antibody (Product # PA5-27349). Sample (30 µg of whole cell lysate). Lane A: HeLa. 10% SDS PAGE. alpha Galactosidase Polyclonal Antibody. alpha Galactosidase Polyclonal Antibody (Product # PA5-27349) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: alpha Galactosidase Polyclonal Antibody detects Galactosidase alpha protein by western blot analysis. Rat tissue extracts (50 µg) was separated by 10% SDS-PAGE, and the membrane was blotted with alpha Galactosidase Polyclonal Antibody (Product # PA5-27349) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: alpha Galactosidase Polyclonal Antibody detects Galactosidase alpha protein by western blot analysis. Whole cell extracts (30 µg) was separated by 10% SDS-PAGE, and the membrane was blotted with alpha Galactosidase Polyclonal Antibody (Product # PA5-27349) at a dilution of 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Western blot-mediated estimation of the semiquantitative profiles noticed for expression of recombinant human alpha1,2-fucosyltransferase (rhalpha1,2-FT) and alpha-galactosidase A (rhalpha-Gal A) enzymes in total protein samples extracted from the ex vivo-expanded control nontransgenic (CTR nTG) PEKs and their cell counterparts stemming from h FUT2 and h GLA single-transgenic pigs and h FUT2 xh GLA double-transgenic specimens. Representative blots corresponding to expression of rhalpha1,2-FT and rhalpha-Gal A enzymes in total protein samples that were isolated from PEKs stemming from h FUT2 mono-transgenic ( a ), h GLA mono-transgenic ( b ), h FUT2 xh GLA bi-transgenic ( c ) and CTR nTG pigs ( d ). beta-Actin provides a loading control for all analyzed protein samples. Results of the semiquantitatively analyzing the relative abundances (RAs) determined for rhalpha1,2-FT and rhalpha-Gal A enzymes (in arbitrary units) were presented in panels ( e , f ), respectively. Bar graphs show mean +- standard error of mean (SEM) of relative optical density (ROD) descended from three separate analyses of three animals for each variant. Red line is taken as the cut-off value 1.0. Statistics: one-way analysis of variance (ANOVA) followed by Tukey's honestly significant difference (HSD) post hoc test. Values that are denoted as ** and *** indicate incidence of statistically significant differences between experimental groups with a probability of occurring random errors at the level

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Western blot analysis of the relative expression of human alpha1,2-fucosyltransferase (alpha1,2-FT) and alpha-galactosidase A (alpha-Gal A) proteins in porcine bi-transgenic and non-transgenic adult cutaneous fibroblast cells (ACFCs) undergoing or not undergoing treatment with trichostatin A (TSA + and TSA - , respectively). Representative blots of the expression of alpha1,2-FT and alpha-Gal A proteins in the ACFC samples derived from epigenetically modulated (TSA + ) and non-modulated (TSA - ) cells. The samples of non-transgenic animals served as a control group (CTR nTG--panel ( A )). beta-Actin served as a loading control for all analyzed samples. The results of relative expression (in arbitrary units) of alpha1,2-FT and alpha-Gal A are shown in panels ( B , C ), respectively. Relative optical density (ROD) from three separate analyses of at least three animals for each variant is expressed as mean. Bar graphs show mean +- standard error of the mean (SEM). The red line is taken as the cut-off value 1.0. Statistics: One-way ANOVA and Tukey's honestly significant difference (HSD) post hoc test. The bars marked with different letters differ significantly; values denoted as a-b, a-d, b-c, b-d, e-f: p < 0.01; a-c, c-d, e-g, f-g: p < 0.05.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Acetylsalicylic acid is a PC-enhancer. IF-GLA-MUTs, specifically C56Y ( A ), L300F ( B ), D244H ( C ), V269M ( D ), and Q280K ( E ), were treated for 72 h with the following drugs: i. untreated; ii. 10 muM DGJ; iii. 4 mM acetylsalicylic acid (ASA); iv. 10 muM DGJ + 4 mM ASA. IF- was used as a control ( F ). AGAL specific activity measured on protein extracts is shown. Tukey's HSD was used to evaluate significative differences among treatments (***: p < 0.001; **: p < 0.01; *: p < 0.05; n = 2). The effects of combined treatment (DGJ + ASA) are significantly higher than those of DGJ monotherapy. Immunoblots confirmed the results (U = untreated; D = DGJ 10 muM; A = ASA 4 mM; D + A = DGJ 10 muM + ASA 4 mM). Each panel includes specific activity and an immunoblot for a cell line.

PA5-27349

Antibody data